RHHBY•benzinga•
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Summary
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 12, 2025 by benzinga